TEVA PHARMACEUTICAL FIN LLC's ticker is and the CUSIP is 88163VAE9.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $2,382,000 | -8.8% | 2,165,000 | -0.7% | 0.02% | 0.0% |
| Q3 2016 | $2,612,000 | -6.0% | 2,180,000 | -1.3% | 0.02% | 0.0% |
| Q2 2016 | $2,778,000 | +0.3% | 2,208,000 | +4.2% | 0.02% | +5.6% |
| Q1 2016 | $2,769,000 | -17.8% | 2,120,000 | -1.4% | 0.02% | -14.3% |
| Q4 2015 | $3,367,000 | +24.6% | 2,150,000 | +8.3% | 0.02% | +10.5% |
| Q3 2015 | $2,702,000 | -74.7% | 1,985,000 | -73.9% | 0.02% | -71.2% |
| Q2 2015 | $10,672,000 | -27.4% | 7,609,000 | -23.2% | 0.07% | -28.3% |
| Q1 2015 | $14,704,000 | +8.1% | 9,902,000 | -0.2% | 0.09% | +2.2% |
| Q4 2014 | $13,607,000 | -8.6% | 9,923,000 | -14.1% | 0.09% | -9.1% |
| Q3 2014 | $14,889,000 | -0.8% | 11,553,000 | -1.5% | 0.10% | +4.2% |
| Q2 2014 | $15,007,000 | -11.6% | 11,724,000 | -12.0% | 0.10% | -12.0% |
| Q1 2014 | $16,970,000 | +19.5% | 13,316,000 | +0.0% | 0.11% | +20.0% |
| Q4 2013 | $14,201,000 | -5.1% | 13,311,000 | -7.3% | 0.09% | -4.3% |
| Q3 2013 | $14,958,000 | -8.1% | 14,357,000 | -7.1% | 0.09% | -11.3% |
| Q2 2013 | $16,271,000 | – | 15,459,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Southpaw Asset Management LP | 20,000,000 | $17,675,000 | 25.38% |
| INCOME RESEARCH & MANAGEMENT | 23,109,000 | $20,278,000 | 5.29% |
| Fore Capital, LLC | 5,000,000 | $4,430,000 | 1.71% |
| RIVERHEAD CAPITAL MANAGEMENT LLC | 20,000,000 | $17,603,000 | 0.74% |
| ARISTEIA CAPITAL, L.L.C. | 18,500,000 | $16,361,000 | 0.70% |
| ZAZOVE ASSOCIATES LLC | 11,153,000 | $9,843,000 | 0.58% |
| BASSO CAPITAL MANAGEMENT, L.P. | 3,600,000 | $3,182,000 | 0.52% |
| CSS LLC/IL | 10,450,000 | $9,240,000 | 0.45% |
| Lombard Odier Asset Management (Europe) Ltd | 7,950,000 | $7,038,000 | 0.44% |
| Wellesley Asset Management | 6,740 | $5,948,000 | 0.31% |